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ABSTRACT
MORGAN ALEXIS CAWTHON: Patient Experiences with Small-Scale Pharmacy
Compounding

Investigators examined patients’ use, knowledge and perceptions of
pharmacy compounding at an independent compounding pharmacy in Mandeville,
Louisiana. Data were collected using a self-administered survey that patients could
complete in hard-copy in the pharmacy or at home, or online using Qualtrics.
Investigators found that, in some instances, patients who use compounded
medications, or have a member of their household who uses compounded
medications, may be more knowledgeable or have more positive perceptions of
compounded medications. However, patients who did not have experience with
compounds were not unknowledgeable about the practice and did not report any
negative perceptions of compounding. These overall positive perceptions and high
level of knowledge about compounded medications may be a product of this specific
pharmacy, and the culture that the compounding pharmacist has created there, but
further, in-depth, longitudinal, quantitative, and qualitative research is needed to
confirm these findings. Furthermore, research is needed to determine if this trend is
seen in other compounding pharmacies, and for other pharmacy services. Future
confirmation of these findings has significant implications for pharmacists, and how
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the culture they create in their pharmacy can lead to enhanced knowledge, positive
perceptions, and increased satisfaction among patients.

v

TABLE OF CONTENTS

LIST OF TABLES…………………………………………………………………………………………………vii
LIST OF FIGURES………………………………………………………………………………………………viii
LIST OF ABBREVIATIONS…………………………………………………………………………………….iv
INTRODUCTION…………………………………………………………………………………………………...1
BACKGROUND……………………………………………………………………………………………………..4
METHODS………………………………………………………………………………………………………….15
RESULTS……………………………………………………………………………………………………………19
DISCUSSION…………………………………………………………………………………………………….…37
REFERENCES……………………………………………………………………………………………………..42
APPENDICES……………………………………………………………………………………………………...45

vi

LIST OF TABLES
Table 1:

Demographic Characteristics

Table 2:

Recipients of Compounds

Table 3:

Number of Compounds Received in the Past Year

Table 4:

Types of Compounds Received

Table 5:

Respondent Reasons for Using Compounds

Table 6:

Legally Acceptable Uses for Compounded Medications

Table 7:

Respondent Satisfaction with Compounded Medication

Table 8:

Respondent Agreement with Statements

vii

LIST OF FIGURES
Figure 1:

Legally Acceptable Compound Use Perceptions

Figure 2:

Familiarity with NECC Outbreak

Figure 3:

Familiarity with Pharmacy Compounding

Figure 4:

Familiarity with Pharmacy Compounding among Compound Users

Figure 5:

Familiarity with Pharmacy Compounding among Compound NonUsers

Figure 6:

Support for Pharmacy Compounds (All Respondents)

Figure 7:

Support for Pharmacy Compounds by Compound Users

Figure 8:

Support for Pharmacy Compounds by Compound Non-Users

viii

LIST OF ABBREVIATIONS
FDA

Food and Drug Administration

BHRT

Bioidentical Hormone Replacement Therapy

NECC

New England Compounding Center

ASHP

American Society of Health-System Pharmacists

FDAMA

Food and Drug Administration Modernization Act

USP

United States Pharmacopeia

USPC

United States Pharmacopeial Convention

FDCA

Food, Drug and Cosmetic Act

TPN

Total Parenteral Nutrition

CPG

Compliance Policy Guide

ACOG

American College of Obstetricians and Gynecologists

PPI

Patient Package Insert

DQSA

Drug Quality and Security Act

IRB

Institutional Review Board

MTM

Medication Therapy Management

ix

INTRODUCTION
According to the Food and Drug Administration (FDA), prescription
compounding is defined as “a practice in which a licensed pharmacist, or…a person
under the supervision of a licensed pharmacist, combines, mixes, or alters
ingredients of a drug to create a medication tailored to the needs of an individual
patient” (Food and Drug Administration, 2013). The Drug Quality and Security Act
defines compounding as “the combining, admixing, mixing, diluting, pooling,
reconstituting, or otherwise altering of a drug or bulk drug substance to create a
drug” (Pharmaceutical Compounding Quality and Accountability Act, 2013). Darrell
Pesta, a pharmacist in the Boston area describes it as “making stuff that doesn’t
exist,” and Scott Vallee, a pharmacist in southern Louisiana described it as “the art
and science of creating personalized medication based on prescriptions from
practitioners” (personal communications, December 16, 2014, March 20, 2015).
Prescription compounding is a wide and varied field that has grown in popularity in
recent years, and many of its aspects are not as concrete and well known as more
traditional prescription dispensing, as shown by the multiple definitions that can be
used to describe the practice of compounding.
In the 1800s, compounding was common practice for a pharmacist, if not the
main portion of his job. Then, in the early 1900s, the industrial revolution hit, and
medications began to be produced in large quantities in multiple strengths and
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doses (Peterson, 2014). This left the pharmacist with little compounding to do, as
there was not much need for individual medicine preparations for individual
patients. As a result, prescription compounding decreased in popularity and
prevalence until about the 1990s. At that point, interest in compounding was
rekindled with the growing demand for veterinary preparations as well as
“Bioidentical Hormone Replacement Therapy,” also known as BHRT, for the
treatment of menopause in women. Both of these have remained as major markets
for compounded medications to this day, with “upwards of two million women in
the US [using compounded hormones] on a daily basis for relief of symptoms
associated with menopause and perimenopause” (Benda, 2006). As women, along
with many other demographic groups, and pets benefitted for years from the fact
that their medications could be tailored to their needs, misfortune struck the
compounding industry in 2012 with the fungal meningitis outbreak from the New
England Compounding Center (NECC). Between May and October of that year, vials
of compounded methylprednisolone injections were inadvertently contaminated
with the fungus and distributed to other states (Peterson, 2014). This was not the
first contamination event to occur in the field of compounding, but it certainly got
the most press and media attention. As a result, the reaction to compounding by the
public was not a good one. Even today, more than two years after the cases
occurred, many patients are wary of compounding and compounded medications.
In order to explore patient perspectives of compounded medications,
searches were done in an effort to identify previous studies of patients’ experiences
with compounding—specifically small-scale compounding done for individual
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patients in community pharmacies. No studies were identified from the patient’s
perspective, so the literature reviewed for this study focused on the history of
compounding and the compounding regulations that have been levied over the
years. The objectives of this study are:
1. To describe the prevalence of compounded medication use by respondents
in a local community pharmacy.
2. To determine the types of compounds respondents use, as well as why
respondents use compounds.
3. To examine patient knowledge and familiarity of small-scale, personal
compounding done in a local community pharmacy.
4. To examine patient satisfaction and perceptions of small-scale, personal
compounding done in a local community pharmacy.
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BACKGROUND
Defining Compounding
Compounding is a field that is not very well understood, much less easy to
define. There appears to be a fine line between compounding and manufacturing of
prescriptions, as well as questions about whether something as simple as
reconstituting a retail antibiotic suspension is considered to be “compounding.”
According to the American Society of Health-System Pharmacists (ASHP),
compounding is a process where “a medicine has to be created because the strength,
concentration, or dosage form that is needed for a specific patient is not
commercially available,” and is under the supervision of state boards of pharmacy,
rather than the federal government (Flaker, 2012). With this definition, simple
processes like reconstituting an antibiotic or mixing a Magic Mouthwash are not a
form of compounding because the medications are commercially available
preparations. Manufacturing, as termed by ASHP, is “the preparation of large
quantities of medication with a process that is approved and regulated by the U.S.
Food and Drug Administration (FDA). Under this process, manufacturers must
comply with federal quality and safety standards” (Flaker, 2012).
Even when making a medication specific for a patient, there are certain
criteria that must be met. The compound must be made for an ethical, approved use,
only approved ingredients may be used, and only certain amounts may be made in a
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single sitting (Allen, 2003). Medications can only be compounded for a patient if the
medication that the patient requires is not already commercially available, or if
what is commercially available is not suitable for the patient. Allergies or adverse
reactions to inactive ingredients like dyes, preservatives, or fillers are acceptable
uses for compounding. It can also be used if a specific dosage strength or dosage
route is not commercially available, or if the physician prescribes a medication in
which multiple commercially available products are combined into a single capsule
or cream, to be administered together (personal communication, March 20, 2015).
There are also medications that have multiple clinical uses, but only one use is FDA
approved as an indication. In this case, a compound can only be made for the
indicated use. For example, domperidone has a FDA-approved use is as a
gastrointestinal aid to increase GI movement and prevent nausea and vomiting, but
there are studies that show that it can be used to increase lactation in women. This
however was found to cause dangerous heart problems in nursing women, so the
FDA removed it as an acceptable medication for women who are nursing (Food and
Drug Administration, 2013). As a result, only prescriptions for domperidone from
gastroenterologists are accepted as an appropriate order to compound the
medication. Compounds must also consist entirely of approved ingredients. The FDA
Modernization Act of 1997 (FDAMA) legislated that “compounding must be done
using ingredients that had US Pharmacopeia/National Formulary (USP/NF)
monographs, were components of commercial products, or appeared on a list of
approved bulk drug substances that was to be developed by the FDA” (Allen, 2003).
Estriol, an estrogen product used in the treatment of menopause, is an ingredient

5

affected by this law. The FDA states that only pharmacies with valid investigational
new drug applications may compound medications containing the estrogen
substance (2013). Ingredients that prove to be difficult or potentially dangerous to
compound are also not approved. Compounding pharmacists are also limited to the
amount of a compound they can make at one time. Legally, the quantity of the
compounded medication made is only to be sufficient for the individual patient
prescription for which the physician wrote. These restrictions are also outlined by
the FDAMA, stating that a pharmacist could not compound drug products that were,
for intents and purposes, copies of commercially available products, drugs that
could present “demonstrable difficulties for compounding,” and may not use an
ingredient that is on a list of ingredients that has been removed from the market for
efficacy or safety reasons (Allen, 2003). For this reason, compounds must be made
in small, patient-specific batches, with no excess to be saved for use at a later date.
History of Compounding Regulation
The history of compounding regulation is much more extensive than
determining appropriate ingredients, uses, and quantities. The practice of
compounding has been around since the medieval times, when medications were
made of fats and herbs in individual doses, only when requested by a doctor, for a
single patient. The late 1700s and early 1800s brought with it the Industrial
Revolution, which put compounding largely on hold. The Industrial Revolution saw
the rise of drug manufacturing companies, churning out copious amounts of drugs
offered in only one or two strengths, making the process of providing medication
more standardized and economical than preparing individualized compounds
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(Petersen, 2014). In 1820, the United States Pharmacopoeia (USP) was established
with the intent of setting “standards (for quality, strength, purity) for drug products
that were prescribed by physicians and prepared (compounded) by pharmacists”
(Allen, 2003). The USP was used until the early 1900s as the standard for
pharmaceutical compounding in the United States, mainly with regard to natural
ingredients. An official set of quality and purity standards was set for the United
States in 1906 with the US Pharmacopeial Convention (USPC), and is still in effect
today, supplemented by more recent legislation. Chapters 795, 797, 1075, and 1160
of the USPC pertain directly to compounding ingredients and practices for sterile
and non-sterile compounding (Allen, 2003). The Pure Food and Drug Act was also
passed in 1906, and was designed to regulate the shift that the pharmaceutical
industry was experiencing from small-scale compounding of medications to large
scale manufacturing practices (Petersen, 2014).
In 1938, the Pure Food and Drug Act was replaced by the Food, Drug and
Cosmetic Act (FDCA), which played a large role in setting up the current US Food
and Drug Administration, or FDA (Pergolizzi et. al, 2013). This allowed
compounding to be used as a way for doctors to “special order” medications that
were not commercially available for a patient, in order for the patient to receive
optimal dosing. Pergolizzi states that this is when pediatric medication increased in
popularity, because doctors were no longer tied to the pill-form dosages that were
too strong for infants (2013). They could have the dosages cut, or the medication
made into a liquid, in order to facilitate the needs of the child. The FDCA also stated
that compounding pharmacies, unlike drug manufacturers, were not under the
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regulations of the FDA, because they were not actually manufacturing drugs, due to
the small batch sizes. Instead, compounding pharmacies were deemed to be
regulated by state boards of pharmacy, unless a manufacturing-type offense were
committed, which would allow the FDA to intervene (Pergolizzi et. al, 2013).
The 1960s and 70s opened up doors to new types of compounding. As
technology advanced, the possibility for medications to be offered in single-dose
vials and syringes arose and became very popular. By only using a syringe or vial
once, the sterility of the drug could be better guaranteed than that of a multi-use
vial. This idea won favor among doctors, nurses, and patients, and the compounding
of TPNs, and repackaging of medication into single-use administrations became
more of a common practice (Pergolizzi et. al, 2013). In the 1990s, veterinary
compounds and Bioidentical Hormone Replacement Therapies (BHRT) became a
hot new topic in the compounding industry. Veterinarians had the ability to write
prescriptions for an animal, using human medications with altered dosages, fillers,
or flavorings. Studies show that the 1990s are also when people began to spend
more money on their pets with fancy outfits and toys, specialty veterinarians, as
well as medications better tailored to their animals (Petersen, 2014). Petersen also
shares that compounded hormone therapy also became more popular in the 90s, as
it offered women, as well as men, many more hormone options than the select few
that were commercially available, and physicians could more specifically target the
causes or symptoms of the patient’s hormone imbalances (2014).
1992 brought the next round of compounding regulations, with the FDA
publishing its first Compliance Policy Guide, or CPG. Because it was published by the
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FDA, who legally did not have jurisdiction over compounding pharmacies, the guide
was not enforceable, but provided very detailed guidelines on expected procedures
and practices in a compounding pharmacy (Allen, 2003). Allen states that the CPG
explained the criteria that would classify a pharmacy as a manufacturer versus a
compounding pharmacy, and would therefore make the establishment subject to
regulation by the FDA, rather than the state board of pharmacy (2003). In 1997,
official legislation, by the name of the Food and Drug Administration Modernization
Act (FDAMA), was passed and allowed the FDA to have a bigger role in the
regulation of compounding, declaring it the official regulatory board, rather than the
state boards of pharmacy (Petersen, 2014). With their new authority, the FDA began
to investigate pharmacies that they felt were “manufacturing under the guise of
compounding” (Allen, 2003). This was a major change for compounding pharmacies,
and many of them challenged the restrictions, with a few cases making it to the US
Supreme Court (Petersen, 2014). The passage of the FDAMA was helpful to
compounding pharmacies with regard to New Drug Applications, however. The Act
declared that if the new prescription is being compounded based off of a physician’s
orders, for a single patient, then the new drug requirements do not apply to that
drug (Allen, 2003).
The practice of compounding has dealt with more than the passage of a few
laws over the years and has had its share of outbreaks and media attention as well.
The first was in 2002, with a fungal meningitis outbreak following the
administration of injections that were found to be contaminated with Exophiala
dermatitidis from a compounding pharmacy in North Carolina, killing 6 patients
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(Pergolizzi et. al, 2013). The FDA has also dealt with complaints from the drug
manufacturers, in regards to compounding. Wyeth Pharmaceuticals, the
manufacturers of the commercially available hormone replacement drugs Premarin
and Prempro, put pressure on the FDA to delve deeper into the regulations in place
regarding pharmacists making BHRT drugs. The manufacturer argued that was
stealing a significant portion of their FDA-regulated business, partly because those
pharmacies did not have to answer to FDA regulation (Benda, 2008). At the center
of the dispute was the term “bioidentical,” which compounding pharmacies used to
describe their hormone replacement therapies. The Endocrine Society defines
“bioidentical” pertaining to hormone compounds as “compounds that have exactly
the same chemical and molecular structure as hormones that are produced in the
human body” (Files et. al, 2011). Similarly, the American College of Obstetricians
and Gynecologists (ACOG) states that:
Bioidentical hormones are plant-derived hormones that are
chemically similar or structurally identical to those produced by the
body. Bioidentical hormones include commercially available products
approved by the U.S. Food and Drug Administration (FDA), such as
micron-ized progesterone and estradiol, as well as compounded
preparations that are not regulated by the FDA (2012).
Wyeth was arguing that compounding pharmacies that were offering or advertising
“bioidentical” hormone therapies were taking a large portion of their business,
falsely advertising the benefits of compounded hormones versus manufactured
ones, and because they were not regulated by the FDA, were getting away with it
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(Benda, 2008). In October of 2005, Wyeth Pharmaceuticals submitted a citizen’s
petition to the FDA, asking the FDA, among other things, to classify compounded
BHRT products as “new drugs,” making them subject to all of the same FDA criteria
that Wyeth was subject to (Benda, 2008). In his article, William Benda states that
the petition asked for enforcement against pharmacists that were compounding or
advertising BHRT products and were in violation of the FDCA, for investigation into
whether compounding pharmacies were dispensing PPIs and facts and risk
information with their compounds, for compounding pharmacists to be required to
disclose certain things on their BHRT labels, and for another CPG to be issued
discussing the concerns associated with BHRT medications (2008). The petition
made it all the way to the Supreme Court, where all of the requests made by Wyeth
Pharmaceuticals were denied, particularly the one requesting that compounded
BHRTs be subject to new drug testing. The court’s ruling was that “it would not
make sense to require compounded drugs created to meet the unique needs of
individual patients to undergo the testing required for the new drug approval
process…requiring such testing would force pharmacists to stop providing
compounded drugs” (Benda, 2008). Furthermore, Benda states that many patients
and physicians were documented as being on the side of the compounded BHRT
prescriptions, rather than the commercially available ones, like those manufactured
by Wyeth, among others (2008).
The compounding industry remained outbreak-free until 2011, when
multiple cases of Serratia, caused by the bacteria Serratia marcescens, were
determined to have been linked to contaminated total parenteral nutrition (TPN)
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bags that were compounded by a pharmacy in Alabama and distributed in the
surrounding areas (Pergolizzi et. al, 2013). In 2012, there was a multi-state
outbreak of endopthalmitis, traced back to contaminated vials of intraocular
injections of bevacizumab, along with the well-known fungal meningitis outbreak
traced back to the New England Compounding Center (NECC) (Pergolizzi et. al,
2013). The NECC contamination event is the most influential of these outbreaks, due
to the large amount of media attention that it got, and the vast area that the
infections covered. Because the NECC is a manufacturer of compounded
medications, like the methylprednisolone vials that were affected, its products were
shipped outside the states borders, putting more than just the customers of
Massachusetts at risk of infection. The NECC outbreak received such a significant
amount of media attention due to the large number of deaths and hospitalizations
caused. The injections, contaminated with the Exserohilium rostratum fungi, were
administered in the spinal cords of patients, giving the fungus access to the
meninges, causing fungal meningitis, which is very difficult to treat (Centers for
Disease Control, 2013). Because of the geographical spread of the infected vials, and
the prolonged, intense media exposure that the situation received, havoc broke out
in the United States for multiple months as new cases popped up across the nation.
In response to the chaos and worry that was caused by the NECC event, the
FDA issued the Drug Quality and Security Act (DQSA) in 2013. The legislation
distinguishes between a compounding pharmacy and compounding manufacturers,
“which make sterile products without or in advance of a prescription and sell those
products across state lines” (Food and Drug Administration, 2013). The Act is
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divided into two sections. The first section, the Compounding Quality Act sets up a
compliance system in which compounding pharmacies can voluntarily deem
themselves as “outsourcing facilities” and be subject to the same supervision by the
FDA as pharmaceutical manufacturers (Looser, 2013). Once registered as an
outsourcing facility, the compounding pharmacy must pay fees to the FDA, ensure
that the labels on their compounded medications clearly indicate that the drug is
compounded, along with many other pieces of information for the patient, and be
subject to risk-based inspections, initiated by the contents of the adverse event
reports that the outsourcing facilities are required to submit (McGuire-Woods,
2013). The Act also states that the FDA was in the process of developing a new list of
drugs that may not be used in compounds, as well as bulk ingredients that will be
permitted. The second section of the DQSA is the Drug Supply Chain Security Act,
which requires that all manufacturers put barcodes on their products from the very
beginning of manufacturing. The barcode can be used to track products through
every step of the manufacturing process, as well as through the distributing and
dispensing steps (Food and Drug Administration, 2013).
Because of all of the events that have occurred recently, there is an
understandable possibility that consumer and public opinions of compounding have
been affected. Between the news coverage and the talk of new legislation as a result
of a widespread compounding manufacturing contamination error, the general
public, along with any healthcare professional not familiar with compounding
practices, received a very biased and dramatized representation of the
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compounding industry. The lasting effect of this representation has yet to be
studied.
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METHODS
Design
This study was conducted using an observational, cross-sectional,
descriptive, non-experimental survey design. A cross-sectional study is a method of
data collection, in which all data are gathered at one point in time, rather than
multiple times over an extended period of time.
Sample
The sample frame for this study consisted of any patients, age 18 or older, of
C and C Drugs Vital Care, an independent retail pharmacy in Mandeville, Louisiana.
This setting was chosen for this study because, unlike the other chain or
independent pharmacies in the area, it offers compounded medications. A variety of
patients use these compounded medications, including children, animals, men,
women, and elderly patients. A total of 175 paper surveys and 1300 links to the
electronic version of the survey were made available to patients of the pharmacy.
Data Collection
Before any surveys were administered, an application for exempt status was
submitted to the University of Mississippi Institutional Review Board (IRB). The
University of Mississippi IRB indeed designated the study as exempt, and surveys
were then allowed to be distributed and data to be collected. The study offered two
ways in which to complete the survey: a paper copy that could be filled out while in
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the pharmacy or taken home and brought back at the patient’s convenience, and a
website address that linked to the survey, generated using Qualtrics. Refer to
Appendix A for the survey questions that were administered. Each form of the
survey given included a cover letter explaining the study, and instructions on how to
complete it. Refer to Appendices B and C for these letters.
The first few questions in the survey were basic demographic questions, such
as gender, age, ethnicity, education, employment status, and household income. The
survey also contained questions about patients’ use, knowledge and perceptions of
the small-scale pharmacy compounding that was done at C and C Drugs Vital Care,
the pharmacy where they get their medications filled. Patients who had received
compounded medications, either for themselves, a relative, a child, or pet were
prompted to answer more detailed questions about the kinds of compounds they
received, what they understood compounded medications to be for, and their
opinions on the compounded medications they had received. The survey then asked
all participants about their perceptions of the kind of small-scale pharmacy
compounding done at C and C Drugs Vital Care, and of the New England
Compounding Center fungal meningitis outbreak. Levels of agreement were used in
multiple questions to describe levels of familiarity
Data Management
After closing data collection, surveys completed in Qualtrics were
downloaded to an Excel 2013 spreadsheet. On this spreadsheet, investigators
entered data from the paper surveys. An additional field was added to the
spreadsheet to indicate survey numbers. Numbers on the spreadsheet matched
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numbers that were placed on the paper survey in order to allow the investigators to
cross-reference papers surveys with the dataset as necessary. After all paper survey
data were entered, the data was uploaded into IBM SPSS Statistics 22 for data
analysis.
Analysis
Sample Description. A sample description was generated by calculating
means, frequencies and percentages as appropriate for each demographic
characteristic measured among participants.
Prevalence of Compound Use. Frequencies and percentages were used to
describe the prevalence of compound use among respondents.
Types of Compounds Used/Reasons for Use. Frequencies and percentages were
used to describe the types of compounds used among respondents as well as why
respondents use compounds. A Chi-Square test of Independence was conducted to
determine if the type of compound used varied according to patient age.
Knowledge and Familiarity. Patient knowledge and familiarity were analyzed
using frequencies, percentages, and Pearson Chi Square tests of Independence.
Frequencies and percentages were used to analyze questions about awareness of
availability of compounding at C and C Drugs Vital Care, legal uses for compounding,
and familiarity with compounding in general, as well as the New England
Compounding Center (NECC) event. Chi Square analyses were conducted to test for
differences in knowledge between respondents who received compounds and those
who did not receive compounds to determine whether the differences in their
knowledge were statistically significant.
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Satisfaction and Perceptions. Patient perceptions were analyzed using
frequencies and means, along with Chi Square tests to determine statistically
significant differences between groups. Means were calculated to establish an
average satisfaction or agreement score on questions regarding receipt of a
compound and patient-pharmacist relationships related to compounding. Chi
Square analysis was used to examine statistically significant differences between
those who did and did not receive compounds with regard to how supportive they
were of pharmacy compounding.
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RESULTS
Response Rate
Although the number of paper surveys and survey links available is known
(175 and 1300, respectively), it is possible that individual patients may have
received the survey or link multiple times as a result of multiple visits to the
pharmacy. Therefore, a response rate was not able to be calculated. At the
conclusion of data collection, 81 electronic and 60 paper surveys were received. Of
the 141 total surveys received, 7 were not included in data analysis due to the
surveys being incomplete. Therefore, a resulting 134 total surveys were used for
data analysis.
Sample Description
In order to better understand some of the characteristics of respondents,
multiple demographic questions were asked. Of the 134 completed surveys, 27
(20.1%) were completed by males, and 107 (79.9%) were completed by females.
The minimum age to complete the survey was 18 years old. Participant ages ranged
from 18 to 80 years of age, with a mean age of about 50 (49.59) years. The majority
of respondents reported their race as Caucasian, with 129 of 134 (96.3%)
respondents designating it as their nationality. Respondents’ highest levels of
education were more varied, with Bachelor’s degree and some college completed
being the most common responses at 32.1% and 23.9%, respectively. In terms of

19

employment status, 47.8% of respondents had full-time jobs. When asked about
their total household income, only 129 of the 134 respondents chose to answer the
question. Most of the respondents reported a total household income of $80,000 per
year or more. Additional sample characteristics can be found in Table 1.

Table 1: Demographic Characteristics
Nationality
African-America
American Indian/Alaska Native
Asian/Asian Indian
Caucasian (white)
Hispanic
Native Hawaiian/Pacific Islander
Other
Highest Level of Education
Some grade school
Some high school
High school diploma or GED
Some college
Vocational degree
Associate’s degree
Bachelor’s degree
Master’s degree
Doctoral degree
Professional degree (MD, etc.)
Employment Status
Full-time
Part-time
Unemployed
Student
Retired
Disabled
Total Household Income*
Less than $10,000
$10,000 to $19,999

Number of Respondents (%)
2 (1.5)
0 (0)
1 (0.7)
129 (96.3)
2 (1.5)
0 (0)
0 (0)
Number of Respondents (%)
0 (0)
3 (2.2)
26 (19.4)
32 (23.9)
4 (3.0)
5 (3.7)
43 (32.1)
11 (8.2)
5 (3.7)
5 (3.7)
Number of Respondents (%)
64 (47.8)
20 (14.9)
11 (8.2)
9 (6.7)
24 (17.9)
6 (4.5)
Number of Respondents (%)
4 (3.0)
9 (6.7)
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$20,000 to $29,999
$30,000 to $39,999
$40,000 to $49,999
$50,000 to $59,999
$60,000 to $69,999
$70,000 to $79,999
$80,000 to $89,999
$90,000 to $99,999
$100,000 to $149,999
$150,000 or more
*Total number of respondents = 129

6 (4.5)
7 (5.2)
7 (5.2)
6 (4.5)
9 (6.7)
5 (3.7)
11 (8.2)
10 (7.5)
30 (22.4)
25 (18.7)

Prevalence of Compound Use
Respondents were asked to indicate if they themselves, a spouse or
significant other, a child, a pet, or no one in their household had ever received a
compounded medication. Respondents were asked to select all answers that
applied. The most common responses were “myself” and “no one,” with frequencies
of 60 and 50 responses, respectively. There were a total of 83 surveys that indicated
that they either received a compound themselves, or had a household member that
got one, and 51 respondents indicated no one in their household had ever received a
compounded medication. Other data pertaining to the distribution of association
with compounds can be found in Table 2.
The respondents that reported having a household association with
compounded medications were then asked to complete an additional set of
questions. The sample size for these questions was 83 (representing the number of
respondents indicating that someone in their household has used a compound),
rather than 134, used in previous questions. They were asked to write in the
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number of different compounds received in the last year, not including refills.
Responses varied from zero to ten. A response of zero indicated that they had gotten
compounds before, just not in the last year. The majority of participants received
one or two compounds in the last year, with those percentages being 24.6% and
17.9% of the 83-respondent sample size, respectively. Additional data on the
number or prescriptions picked up in the last year by those patients that got
compounded medications can be found in Table 3.

Table 2: Recipients of Compounds
Compound Recipient
Myself
Spouse or significant other
Child
Pet
No one

Number of Respondents (%)
60 (44.8)
17 (12.7)
15 (11.2)
17 (12.7)
50 (37.3)

Table 3: Number of Compounds Received in the Past Year
Number of Compounds
0
1
2
3
4
5
6
7
8
9
10

Number of Respondents (%)
15 (18.1)
33 (39.8)
24 (28.9)
6 (7.2)
3 (3.6)
1 (1.2)
0 (0)
0 (0)
0 (0)
0 (0)
1 (1.2)
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Patients who used compounds in their household were also asked to indicate
how many of their compounded medications are covered by insurance (in other
words, not run for a “cash price”). Ten compound users (12%) indicated that they
did not have insurance while 37 (46%) indicated that none of their compounds
were covered by insurance. Twenty-one respondents (26%) indicated that all of
their compounds were covered by insurance. A small number of respondents (13)
indicated that some of their compounds are covered by insurance.
Types of Compounds Used/Reasons for Use
Question 12 asked those participants that got compounds in their household,
what kinds of compounds they get, or what the indications are for them. Of the 83
who got compounds, 33.7% indicated that they or someone in their household got a
compound that was a bioidentical hormone cream or gel, followed by 21.7%
respondents having bought a compounded medication for their pet. Other
dermatologic or anesthetic creams were also common, with 16.9 and 15.7%,
respondents reporting use, respectively. Additional data on what kinds of
compounds respondents reported receiving can be found in Table 4.
Further analysis, using the Chi Square test of Independence was performed to
determine for each type of compound listed in Table 4, if there was a difference in
frequency of usage based on age. To conduct the analysis, age ranges were used.
Based on their reported age, respondents were categorized into four age groups as
utilized by the Census Bureau (18-24, 24-44, 45-64, and 65+). Not surprisingly,
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respondents in the 45-64 age group reported using more bioidentical hormone
creams than respondents in any other age group, X2 (3, N = 134) = 18.4, p < .05.

Table 4: Types of Compounds Received
Kinds of Compounds Received
Bioidentical hormone capsules
Bioidentical hormone creams/gels
Nasal sprays or irrigations
Infusible antibiotics or TPNs
Anesthetic (pain relief/numbing)
Lip balms (cold sores)
Dermatologic creams
Gastroenterological (domperidone)
Magic Mouthwash
Pet medications
Trimix
Vancomycin
Troches or lollipops
Suppositories
Eye or ear drops

Number of Respondents (%)
11 (13.3)
28 (33.7)
5 (6)
4 (4.8)
13 (15.7)
4 (4.8)
14 (16.9)
5 (6)
5 (6)
18 (21.7)
1 (1.2)
2 (2.4)
0 (0)
2 (2.4)
3 (3.6)

Those patients who had received compounded medications themselves or in
their household were asked to indicate why they received a compounded
medication. As indicated by the information above, the most common reasons for
using compounds were “individualized hormone combinations” and “drug not
available for pharmacy to order,” with 34.9% and 30.1% of respondents indicating
those as their reasons for getting compounds, respectively. Another common reason
was to get the drug product in the right dosage form, chosen by 26.5% of
respondents. More than one reason could be chosen, and some may be related to the
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same compounded medication used by the patient. Additional data can be found in
Table 5.

Table 5: Respondent Reasons for Using Compounds
Reasons for Using Compounds
Individualized hormone combinations
Individualized dosages for a child
Individualized dosages for a pet
Drug not available for pharmacy to order
Proper dosage/strength not available to order
More personal patient-pharmacist relationship
Allergies to commercially available drugs
Combine multiple medications into a single dose
Avoid unwanted ingredients
Dosage form needs (cream vs tablet)
Personal preference
Insurance reasons
Addition of flavoring

Number of Respondents (%)
29 (34.9)
10 (12.0)
17 (20.5)
25 (30.1)
12 (14.5)
5 (6.0)
4 (4.8)
16 (19.3)
13 (15.7)
22 (26.5)
9 (10.8)
2 (2.4)
4 (4.8)

Knowledge and Familiarity
Participants were asked if they were aware that C and C Drugs Vital Care
offered compounded medications. Of the 134 respondents, 118 respondents, or
88.1% were aware that compounded prescriptions were an option. Of these 118
respondents aware of compounded prescriptions at the pharmacy, 81 of those
respondents, or 68.6%, had used compounds in their household. This was
significantly higher than respondents who did not use compounds in their
household to be aware of compounds being made at the pharmacy, X2 (1, N = 134) =
15.0, p < .05.

25

All respondents were asked to indicate, from a list of options, what they
thought were legally acceptable uses for compounded medications. Participants
could select as many of the ten options that they thought were legally acceptable
reasons for getting medications compounded. The most commonly selected reasons
were “dosage form needs” and to “combine medications into a single dose,” with 90
and 79 people choosing the options, respectively. Further information on
frequencies for each of the options can be found in Table 6. Additionally, Table 6
outlines which of the uses are legally acceptable, and which are not.
The frequencies for each option were then split into those who reported
themselves, or someone else in their house getting a compounded medication, and
those who had no one in their household receive a compounded medication. The
frequency breakdown of the ten options between those who got compounds, and
those who did not can be found in Figure 1. There was a statistically significant
difference between those who received compounds and those who did not for “drug
not available for pharmacy to order” (X2 (1, N = 134) = 5.4, p < .05) and “proper
dosage not available for pharmacy to order” (X2 (1, N = 134) = 5.6, p < .05). Among
these, those who used compounded medications in their household thought the
reasons mentioned above were legally acceptable uses more frequently than those
who had not gotten a compound.
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Table 6: Legally Acceptable Uses for Compounded Medications
Potential Uses
Drug not available for pharmacy to order
Proper dosage not available to order
Allergy to commercially available version
Combine medications into a single dose
Avoid unwanted ingredients
Personal preference
Children’s dosing needs
Drug shortages
Dosage form needs (cream vs. tablet)
Addition of flavoring

Number of
Respondents (%)
63 (47)
66 (49.3)
61 (45.5)
79 (59)
70 (52.2)
41 (30.6)
71 (53)
31 (23.1)
90 (67.2)
53 (39.6)

Legal Use?
No
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes

Figure 1: Legally Acceptable Compound Use Perceptions

Frequency

Legally Acceptable Compound Uses
among Those Who Use Compounds in
Their Households and Those Who Do Not
70
60
50
40
30
20
10
0

Gets Compounds
Does Not Get Compounds

All respondents were to indicate their level of knowledge about the outbreak
of fungal meningitis that was traced back to the New England Compounding Center
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(NECC). The answer choices ranged from “extremely familiar” to “not at all familiar.”
The majority of respondents reported being “not at all familiar,” with 78% choosing
this option. A summary of responses can be found in Figure 2.

Figure 2: Familiarity with NECC Outbreak

HOW FAMILIAR ARE YOU WITH THE NEW
ENGLAND COMPOUNDING CENTER FUNGAL
MENINGITIS OUTBREAK?
Very, 7,
5%

Extremely
2%

Moderately, 9,
7%
Slightly, 11,
8%

Not at All
78%

All respondents were asked about their familiarity with pharmacy
compounding, from “extremely familiar” to “not at all familiar.” While C and C Drugs
Vital Care dispenses a large amount of compounded medications, about 37% of
respondents reported being moderately familiar and almost 30% reported being
only slightly familiar with compounding. A summary of responses can be found in
Figure 3.
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Additional analysis was done to determine if the familiarity with
compounded medications changed with the personal or household use of a
compound, and then further to determine if the relation to the person that received
the compound changed peoples’ familiarity with the topic. When respondents were
divided into only two groups, one having not received a compounded medication
within their household and the other including all respondents that either had a
household member receive a compounded medication, or they personally had
gotten a compound, a Pearson Chi Square test of Independence was performed to
examine whether or not there was a difference in familiarity between the two
groups. There was found to be a statistical significant difference between the two
groups, with the group who had at least received a household compounds being
more familiar with compounded medications, X2 (4, N = 134) = 35.3, p < .05. Of the
“receives compounds” group, 70% of those included in the group were “moderately
familiar” or more with compounded medications. In the group that did not get
compounds, 76% of respondents reported being “not at all,” or only “slightly”
familiar with compounding. Additional data can be found in Figures 4 and 5.
A third analysis was done to examine whether familiarity changed depending
on the particular person that received the compound. Respondents were split into
three groups: those who claimed no contact with compounded prescriptions, those
who said they had a household member who received a compounded medication,
and those who personally received compounded medications, and may have an
additional household member receive them as well. A Pearson Chi Square test of
Independence was performed on the three groups and a statistically significant

29

difference in familiarity was found between the three groups, X2 (8, N = 134) = 39.8,
p < .05. Higher levels of familiarity were more often found in the group with
personal receipt of a compound, and lowest familiarity in those who had no
connection to compounded medications.

Figure 3: Familiarity with Pharmacy Compounding

HOW FAMILIAR ARE YOU WITH
PHARMACY COMPOUNDING?
Not at All
17%

Extremely
6%

Very
10%

Moderately
37%

Slightly
30%
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Figure 4: Familiarity with Pharmacy Compounding among Compound Users

HOW FAMILIAR ARE YOU WITH
PHARMACY COMPOUNDING? (GETS
COMPOUNDS)
Extremely
7%

Not at All
5%

Very
14%

Slightly
25%

Moderately
49%

Figure 5: Familiarity with Pharmacy Compounding among Compound Non-Users

HOW FAMILIAR ARE YOU WITH
PHARMACY COMPOUNDING? (DOES NOT
GET COMPOUNDS)
Extremely
4%

Very
2%

Not at All
38%
Slightly
38%
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Moderately
18%

Satisfaction and Perceptions
Respondents who received compounds were asked a series of questions
regarding their satisfaction with compounded medications. This first set of
questions was product-focused. They were asked to rate their satisfaction on a
linear numeric scale, with “1” being “not at all satisfied,” and “5” being “very
satisfied.” The average answers to the questions were high, with the highest being
4.68 out of 5 for the safety and quality, and the lowest being 4.10 out of a possible 5
for the cost of the compounds. Additional data on patient satisfaction with
compounds can be found in Table 7.
Other questions were asked to assess how respondents that received
compounded medications felt about more subjective matters, like relationships with
their pharmacist. These questions used a Likert scale with “1” being “strongly
disagree,” and a score of “5” being “strongly agree.” Average scores were not as high
as the satisfaction questions asked in the section before, but still comparatively high,
ranging from 3.53 to 3.90, out of a possible 5. Additional data can be found in Table
8.
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Table 7: Respondent Satisfaction with Compounded Medications*
Frequency (%)
1

2

How satisfied are you, in
2
0
general, with your
(2.5)
(0)
compound?
How satisfied are you with
3
4
the cost of your compound?
(3.8)
(5.1)
How satisfied are you with
1
2
the quality of your
(1.3)
(0)
compound?
How satisfied are you with
0
2
the ease of use of your
(0)
(2.5)
compound?
How satisfied are you with
0
1
the safety of your
(0)
(1.3)
compound?
How satisfied are you with
1
0
the appearance of your
(1.3)
(0)
compound?
How satisfied are you with
0
0
the packaging of your
(0)
(0)
compound?
How satisfied are you with
1
0
the convenience of having a
(1.3)
(0)
compound?
How satisfied are you with
1
0
the performance of your
(1.3)
(0)
compound?
* 1 = not at all satisfied and 5 = very satisfied
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3

Average
(SD)

3
(3.8)

4
13
(16.5)

5
61
(77.2)

4.66
(0.783)

13
(16.5)
4
(5.1)

21
(26.6)
13
(16.5)

38
(48.1)
61
(77.2)

4.10
(1.093)
4.68
(0.690)

6
(7.6)

13
(16.5)

58
(73.4)

4.61
(0.741)

4
(5.1)

14
(17.9)

59
(75.6)

4.68
(0.634)

4
(5.1)

14
(17.7)

60
(75.9)

4.67
(0.693)

4
(5.1)

19
(24.1)

56
(70.9)

4.66
(0.575)

6
(7.6)

13
(16.5)

59
(74.7)

4.63
(0.737)

6
(7.6)

13
(16.5)

59
(74.7)

4.63
(0.737)

Table 8: Respondent Agreement with Statements*
Frequency (%)
1

2

3

I prefer compounded
0
6
46
medications over
(0)
(7.2)
(55.4)
manufactured,
commercially available
medications
Getting compounded
3
5
32
medications leads to a
(3.6) (6.0)
(38.6)
deeper and more personal
relationship with my
pharmacist
Getting compounded
1
4
25
medications leads to a
(1.7) (4.8)
(30.1)
more patient-centered,
rather than drug-centered
relationship with my
pharmacist.
* 1 = strongly disagree and 5 = strongly agree

4

Average
(SD)
5

12
(14.5)

19
(22.9)

3.53
(0.928)

25
(30.1)

18
(21.7)

3.60
(1.011)

25
(30.1)

28
(33.7)

3.90
(0.970)

Respondents were also asked about their support for compounded
medications. Answer choices were the same as the question before it that asked
about familiarity, ranging from “extremely supportive” to “not at all supportive.”
There was also a sixth option, “I don’t know; I have never heard about pharmacy
compounding before taking this survey.” The majority of respondents were
supportive of compounds, with 36% of respondents being “very supportive,” and
34% being “extremely supportive.” Additional data can be found in Figure 6.
Additional analysis was done to determine if those who had received a
compound within the family were more supportive of compounded medications
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than those who had not. The respondents were split into two groups: those who had
compound use in the household, and those who had no connection to compounded
medications. A statistically significant difference was found between the two groups,
with those having a household connection to compounded medications being more
supportive of compounded medications, X2 (4, N = 134) = 34.4, p < .05 The group
that did not get compounds reported more “I don’t know” and “moderately
supportive” answers than the group that received compounds. No participant in
either group reported being unsupportive of compounded medications. Further
data on the differences in answers between the two groups can be found in Figures
7 and 8.

Figure 6: Support for Pharmacy Compounds (All Respondents)

HOW SUPPORTIVE ARE YOU OF
COMPOUNDED MEDICATIONS?
Slightly
4%

I Don't Know
10%
Extremely
34%

Moderately
16%

Very
36%
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Figure 7: Support for Pharmacy Compounds by Compound Users

HOW SUPPORTIVE ARE YOU OF
COMPOUNDED MEDICATIONS? (GETS
COMPOUNDS)
Moderately
11%

Slightly
1%

I Don't Know
1%

Extremely
43%

Very
44%

Figure 8: Support for Pharmacy Compounds by Compound Non-Users

HOW SUPPORTIVE ARE YOU OF
COMPOUNDED MEDICATIONS? (DOES
NOT GET COMPOUNDS)
Extremely
18%

I Don't Know
24%

Very
24%

Slightly
8%
Moderately
26%
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DISCUSSION
Discussion of Findings
This study aimed to measure patients’ use, knowledge and perceptions of
small-scale pharmacy compounding at an independent compounding pharmacy in
Mandeville, Louisiana, C and C Drugs Vital Care. About 20%, of the pharmacy’s
business is comprised of compounded medications, and therefore they are widely
used in the store’s patient population, with some patients using more than one
unique compound. Anecdotally, many of the patients have gotten to know the
compounding pharmacist and tend to be very supportive of him, whether they get
compounds or not. Specifically, positive word-of-mouth, is thought to be a reason
that new patients come to C and C Drugs Vital Care. Many of the findings in this
study may be explained by the support for the compounding pharmacist and his
practice, but further, in-depth, longitudinal, quantitative, and qualitative research is
needed to confirm these findings.
For example, all respondents were asked to report their familiarity with, and
supportiveness of, pharmacy compounding. While there were significant differences
in familiarity and support between those who did and did not have a connection to
compounded medications, even those who did not get compounded medications
were still familiar with or supportive of the practice. Indeed, comments provided by
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some of the respondents at the end of the survey reiterated these findings. For
example, one respondent noted:

“My 38 year daughter has many medical problems, and compounding meds is
extremely valuable to her due to many allergies to many ingredients that are
used, although in small amounts, in many drugs, causing terrible side effects.
Can get just an effective med thru compounding.”

Another respondent less familiar with compounding noted:

“I know very little about pharmaceutical compounding. I assume that it was
more common prior to the mass production of medications in recent times.
Depending on the circumstances, I would think that there is still and will
continue to be a need to pharmaceutical to better serve patients.”

In light of these findings, the characteristics of the study sample should not
be ignored. The vast majority of the respondents described themselves as
Caucasian, highly educated, and making high incomes. Perhaps this sample is a
reflection of the local population, or it could be a self-selection phenomenon. In
other words, this pharmacy may attract this type of patient population because it
does make compounds that may be more expensive and sometimes not covered by
insurance, or this type of population may be more desiring of compounded
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products. That said, there was still concern expressed by a respondent in her
comment about the cost of compounded medications:

“Why is it so expensive? I used to get my compounding cream for $35 and
now it's over $200, therefore I no longer get it because I can't afford it,
although it is like "magic" cream for my pain. It really helps my pain
condition greatly.”

Indeed, nearly 56% of the 83 respondents reported not having insurance or
insurance not covering any of their medications.
Interestingly, those that reported using a compounded medication in their
household more often reported that a “drug not available for the pharmacy to order”
and “proper dosage not available for the pharmacy to order” were legally acceptable
reasons to make a compounded medications. While a proper dosage not being
available is a legitimate reason to compound a medication, a medication not being
available for the pharmacy to order is not. Additionally, 41 of the 134 total
respondents (approximately 31%) indicated that they believed personal preference
was a legally acceptable use for a compounded medication. While not statistically
significant, it was found that more respondents who did not use compounds in their
household thought personal preference was legally acceptable than did respondents
who did use compounded medications in their household. In general, this suggests
that patient education on appropriate reasons for making compounded medications
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may be worthwhile. However, respondents’ interpretation of the questions should
be taking into consideration when exploring these findings.
Another interesting finding was the lack of knowledge of the NECC event that
happened only a few years ago. The reported outcome may have been a function of
how the question was asked. Many patients may have remembered hearing about
the many cases of deadly fungal meningitis that were contracted from an injection,
but they may not have known that the NECC was the organization responsible for
compounding those tainted medications.
Limitations
The topic of pharmaceutical compounds and their perception by the
surrounding patient population can be greatly affected by the setting, which is the
main limitation of this study. The survey was only administered at a single
pharmacy, making it a convenience sample, rather than one that is truly
representative of the whole state or country. Community perceptions may differ in
New England, as the NECC outbreak was a closer threat and may have turned many
patients off of compounding, or in a city that does not have a pharmacy that offers
compounded medications, in which case there is a lack of knowledge of them. By
using only one community to draw data from, and by choosing a pharmacy that was
very involved in the practice of pharmacy compounding, the study is not
generalizable to the rest of the United States or all patient populations.
The motivation of patients within the sample may also affect the
generalizability. Participation was voluntary, so it can be expected that self-selection
bias may result in a much higher ratio of patients who get compounded medications
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participating. The results were not adversely swayed in this study, but there was a
very large percentage of responses that were from patients with a connection to
compounded medications. Pharmacy patients may have also felt more inclined to
complete the survey when they saw that their participation would benefit one of the
employees, someone they knew personally, rather than a survey that was conducted
by someone they did not know.
Conclusions and Implications
Overall, both groups of participants, those who got compounds themselves or
had a household member who received a compound, and those who had no ties to
compounds, had positive perceptions of compounded medications, and were
familiar with the practice. Even those who did not have any connection to
compounded medications appeared familiar with the practice of compounding
medications. Again, this may be due to the culture of C and C Drugs Vital Care and
the efforts by the compounding pharmacist to create an atmosphere and business
that promotes pharmacy compounding and positive perceptions of it by the
patients. However, further, in-depth, longitudinal, quantitative, and qualitative
research is needed to confirm these findings. Future confirmation of these findings
has significant implications for pharmacists, and how the culture they create in their
pharmacy can lead to enhanced knowledge, positive perceptions, and increased
satisfaction among patients. This type of work could be translated to other
compounding practices or any other patient-oriented pharmacy service such as
medication therapy management (MTM).
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Appendix B: Cover Letter for Paper Survey
Dear Patient,
My name is Alix Cawthon, and I am a pharmacy student at Ole Miss. This summer
and fall, I am conducting a research survey through the Sally McDonnell Barksdale
Honors College, and I am asking for your participation. This survey should take no
more than 7 or 8 minutes of your time. It includes various demographic questions,
but mainly focuses on your knowledge and perceptions of pharmacy compounding,
such as the kind done at C and C Drugs Vital Care. We are inviting all customers to
participate, whether you get compounded medications or not. Your willingness to
participate in this research will help me better understand patients’ understanding
and attitude toward small-scale pharmaceutical compounding.
Please keep in mind that your participation in this survey is entirely voluntary. Your
completion of this survey does not affect your patronage at this pharmacy, or with
any of its employees. Your responses will remain completely anonymous and will be
examined along with other respondents’ surveys.
This study has been reviewed by the University of Mississippi’s Institutional Review
Board (IRB). The IRB has determined that this study fulfills the human research
subject protections obligations required by the state and federal law and University
policies. If you have any questions, please contact the IRB at (662) 915-7482.
If you have any questions about the research project specifically, feel free to contact
me at macawtho@go.olemiss.edu, or my advisor, Dr. Erin Holmes, at
erholmes@olemiss.edu, or (662) 915-5914.
Thank you in advance for your participation.
Sincerely,
Alix Cawthon
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Appendix C: Cover Letter for Electronic Survey
Dear Patient,
My name is Alix Cawthon, and I am a pharmacy student at Ole Miss. This summer
and fall, I am conducting a research survey through the Sally McDonnell Barksdale
Honors College, and I am asking for your participation. This survey should take no
more than 7 or 8 minutes of your time. It includes various demographic questions,
but mainly focuses on your knowledge and perceptions of pharmacy compounding,
such as the kind done at C and C Drugs Vital Care. We are inviting all customers to
participate, whether you get compounded medications or not. Your willingness to
participate in this research will help me better understand patients’ understanding
and attitude toward small-scale pharmaceutical compounding. You can access the
survey by typing the link below into your internet browser:
http://tinyurl.com/n7nj89l

Please keep in mind that your participation in this survey is entirely voluntary. Your
completion of this survey does not affect your patronage at this pharmacy, or with
any of its employees. Your responses will remain completely anonymous and will be
examined along with other respondents’ surveys.
This study has been reviewed by the University of Mississippi’s Institutional Review
Board (IRB). The IRB has determined that this study fulfills the human research
subject protections obligations required by the state and federal law and University
policies. If you have any questions, please contact the IRB at (662) 915-7482.
If you have any questions about the research project specifically, feel free to contact
me at macawtho@go.olemiss.edu, or my advisor, Dr. Erin Holmes, at
erholmes@olemiss.edu, or (662) 915-5914.
Thank you in advance for your participation.
Sincerely,
Alix Cawthon
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